The COVID-19 Impact On Sanitization Drives The 1-Decanol Market

1-Decanol Market Report 2020-30: COVID-19 Growth And Change

1-Decanol Global Market Report 2020-30: COVID-19 Growth And Change

The Business Research Company’s 1-Decanol Global Market Report 2020-30: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increased demand for personal care and household cleaning products due to the COVID-19 impact contributed to the growth of the 1-Decanol market. 1-Decanol is used as a raw material in the manufacturing of soaps, detergents, other home care products, and as an anti-foam agent. In 2020, due to the COVID-19 outbreak, the usage and awareness of personal care and home care products such as soaps, detergents and sanitizers have increased so that the spread of the virus can be reduced. According to the World Health Organization, to prevent the infection, one should always wash hands regularly with soap and water or clean hands with an alcohol-based hand rub. The increase in usage of personal care products including soap and sanitizers increased the demand for 1-Decanol, thereby driving the market.

The 1-Decanol market consists of sales of 1-Decanol and related services by entities (organizations, sole traders and partnerships) that manufacture 1-decanol. 1-Decanol is a chain of fatty alcohol that is colorless to light yellow viscous liquid and insoluble in water. 1-Decanol is used in manufacturing plasticizers, lubricants, surfactants.

The global 1-Decanol market is segmented by type into synthetic, natural and by application into plasticizers, lubricants, detergents and cleaners, cosmetics and personal care, pharmaceuticals, flavors and fragrances, others.

Read More On The Global 1-Decanol Market Report:
https://www.thebusinessresearchcompany.com/report/1-decanol-global-market-report

The global 1-Decanol market is expected to grow from $175.95 million in 2020 to $207.37 million in 2021 at a compound annual growth rate (CAGR) of 17.9% according to 1-Decanol market research. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global 1-Decanol market is expected to reach $262.69 million in 2025 at a CAGR of 6.1%. Asia Pacific accounts for the largest 1-Decanol market share. The regions covered in the global 1-Decanol market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

As per TBRC’s 1-Decanol industry analysis, major players in the market are Kuala Lumpur Kepong Berhad (KLK Oleo), Sasol, Musim Mas Holdings, Emery Oleochemicals, BASF SE, Ecogreen Oleochemicals, P&G Chemicals, Berg + Schmidt, Cremer Oleo GmbH, Global Green Chemicals Public, New Japan Chemical, Central Drug House, Chemical Bull, Parchem fine & specialty chemicals, Santa Cruz Biotechnology, Spectrum Chemical Manufacturing, and Thermo Fisher Scientific.

1-Decanol Global Market Report 2020-30: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides 1-Decanol global market overview, forecast 1-Decanol global market size and growth for the whole market, 1-Decanol global market segments, and geographies, 1-Decanol global market trends, 1-Decanol global market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global 1-Decanol Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4023&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Disinfectants Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/disinfectants-market-global-report-2020-30-covid-19-growth-and-change

Surface Active Agents Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/surface-active-agents-global-market-report

Soap And Cleaning Compounds Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/soap-and-cleaning-compounds-global-market-report-2020-30-covid-19-impact-and-recovery
Ethyl Alcohol Global Market Report 2021: COVID-19 Impact and Recovery to 2030

https://www.thebusinessresearchcompany.com/report/ethyl-alcohol-manufacturing-global-market-report-2020-30-covid-19-implications-and-growth

Interested to know more about The Business Research Company?

Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Pyrogen Testing Industry Trends Are Focusing On Animal-Free Testing Such As MAT

Pyrogen Testing Market Report 2020-30: COVID-19 Growth And Change

Pyrogen Testing Global Market Report 2020-30: COVID-19 Growth And Change

The Business Research Company’s Pyrogen Testing Global Market Report 2020-30: COVID-19 Growth And Change

LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Companies are focusing on the evolution of various animal-free pyrogen testing methods such as monocyte activation assay (MAT) to overcome constraints of rabbit pyrogen testing method and LAL test, and to have humane treatment of animals. Pyrogen testing market trends like MAT provide a high level of prediction of pyrogenic activity and this also stimulates fever reaction better than the RPT or BET/LAL. The MAT pyrogen testing method is used to detect both endotoxin and non-endotoxin pyrogens, while the LAL test is limited to detect only endotoxin pyrogen. Merck has focused on two MAT systems for the detection of pyrogens, namely PyroDetect and PyroMAT.

Major players in the pyrogen testing market are Thermo Fisher Scientific, Inc., Merck KGaA, Charles River Laboratories, Inc., Lonza Group, Ellab A/S, Nelson Laboratories Inc., Associates of Cape Cod, Inc., GenScript, BioMerieux, Hyglos GmbH, Sanquin, Wako Chemicals USA, Inc., and Pyrostar.

The global pyrogen testing market is segmented by test type into LAL test, in vitro test, rabbit test, by product and service into assays, kits, reagents, instruments, services, and by application into pharmaceutical and biologics, medical devices, others.

Read More On The Global Pyrogen Testing Market Report:
https://www.thebusinessresearchcompany.com/report/pyrogen-testing-global-market-report

The global pyrogen testing market size is expected to grow from $1.03 billion in 2020 to $1.20 billion in 2021 at a compound annual growth rate (CAGR) of 16.2%. Pyrogen testing market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global pyrogen testing market is expected to reach $1.78 billion in 2025 at a CAGR of 10.4%. North America was the largest region in the pyrogen testing market in 2020. Asia Pacific is expected to continue to be the fastest growing region in the forecast period. The regions covered in the pyrogen testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Pyrogen Testing Global Market Report 2020-30: COVID-19 Growth And Change is one of a series of new reports from The Business Research Company that provides pyrogen testing global market overview, forecast pyrogen testing global market size and growth for the whole market, pyrogen testing global market segments, and geographies, pyrogen testing global market trends, pyrogen testing global market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Pyrogen Testing Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=4020&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Human Microbiome Therapeutics Market – By Disease (Infectious Diseases, Gastrointestinal Disorders, Metabolic Disorders, Cancers, Other Diseases), By Sequencing Technology Type (Targeted Gene, RNA, Whole-Genome Shotgun (WGS), Others Type) And By Region, Opportunities And Strategies – Global Forecast To 2030
https://www.thebusinessresearchcompany.com/report/human-microbiome-therapeutics-market

Microbiome Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/microbiome-market-global-report-2020-30-covid-19-growth-and-change

Pharma Microbiology Testing Kits Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/pharma-microbiology-testing-kits-global-market-report

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Increased Investment In Proteomics And Genomics R&D Leads To Growth In The Protein Labeling Market

Protein Labeling Market Report 2021: COVID-19 Growth And Change To 2030

Protein Labeling Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Protein Labeling Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increased spending on the R&D of proteomics and genomics is driving the growth of the protein labeling reagents market. Proteomics is the study of the overall protein content of a cell, tissue, or organism. Protein labeling methods before separation and analysis is essential during proteomic profiling approaches. For instance, the National Institutes of Health (NIH) of the United States funded $37 billion for biomedical research. This funding is for life sciences research that supports study at a molecular level for the understanding of fundamental processes by which diseases develop identification of biomarkers that signal the presence of disease, or identification of gene/protein responsible for the disease. The Novo Nordisk Foundation granted a grant of up to $1.5 million to the University of Copenhagen to establish a mass spectrometry facility, which marks a new and exciting step in protein research. Therefore, the increased spending on research and development of proteomics and genomics is driving the market.

Read More On The Global Protein Labeling Market Report:
https://www.thebusinessresearchcompany.com/report/protein-labeling-global-market-report-2020-30-covid-19-growth-and-change

The global protein labeling market is expected to grow from $1.6 billion in 2020 to $1.77 billion in 2021 at a compound annual growth rate (CAGR) of 10.6%. Protein labeling market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The protein labeling market is expected to reach $2.79 billion in 2025 at a CAGR of 12%.

Major players in the protein labeling industry are Thermo Fisher Scientific Inc, Merck KGaA, PerkinElmer, Inc., General Electric Company, F. Hoffmann-La Roche AG, AGILENT TECHNOLOGIES INC., BIO-RAD LABORATORIES, Kirkegaard & Perry Laboratories, LI-COR Inc., and Kaneka Corporation.

TBRC’s fluorescent protein market report is segmented by product into reagents, protein, enzymes, probes/ tags, monoclonal antibodies, by labeling method into in-vitro labeling, in-vivo labeling and by application into cell based-assay, fluorescence microscopy, immunological techniques, mass spectrometry, protein micro assay.

Protein Labeling Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides protein labeling market overview, forecast protein labeling market size and growth for the whole market, protein labeling market segments, and geographies, protein labeling market trends, protein labeling market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Protein Labeling Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3417&type=smp

Here Is A List Of Similar Reports By The Business Research Company:

Protein Expression Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/protein-expression-global-market-report

Protein Inhibitors Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/protein-inhibitors-global-market-report-2020-30-covid-19-growth-and-change

3D Cell Culture Technologies Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/3d-cell-culture-technologies-global-market-report

Cell Based Assays Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/cell-based-assays-global-market-report

Lateral Flow Immunoassay (LFIA) Based Rapid Test Global Market Report 2021: COVID-19 Growth And Change to 2030
https://www.thebusinessresearchcompany.com/report/lateral-flow-immunoassay-lfia-based-rapid-test-global-market-report-2020-30-covid-19-growth-and-change

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Increasing R&D Investments And Collaborations Are Key Trends In The Alzheimer’s Disease Treatment Market

Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

The Business Research Company’s Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030

LONDON, GREATER LONDON, UK, April 1, 2021 /EINPresswire.com/ — Our reports have been revised for market size, forecasts, and strategies to take on 2021 after the COVID-19 impact: https://www.thebusinessresearchcompany.com/global-market-reports

Increasing R&D investments and collaborations due to the emerging technologies for treatment is a key trend in Alzheimer’s disease (AD) treatment market. The Alzheimer's Association is assisting with funds for researchers in search of innovative therapeutic approaches, and seeks more government funding for Alzheimer's studies. Technologies such as ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field on their peptidomimetic series.

Manufacturing companies such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, vTv Therapeutics are more focused on R&D investments with their research molecules in the clinical trials to achieve a breakthrough for the treatment of AD.

Other AD market trends include mergers and acquisitions. In January 2020, Biogen Inc., an American multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development and manufacture of healthcare products including medicines and vaccines.

Major players in the global Alzheimer's disease drugs market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd.

Read More On The Global Alzheimer’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/report/alzheimers-disease-treatment-global-market-report-2020-30-covid-19-growth-and-change

The global Alzheimer’s disease treatments market is expected to grow from $3.43 billion in 2020 to $3.76 billion in 2021 at a compound annual growth rate (CAGR) of 9.6%. The growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global Alzheimer’s disease treatment market is expected to reach $5.91 billion in 2025 at a CAGR of 12%.

The global Alzheimer's disease market is segmented by drug class into cholinergic, memantine, combined drug, AChE inhibitors, immunoglobulins, by drug type into cholinesterase inhibitors, NMDA receptor antagonists, and by therapeutics into cholinesterase inhibitors, NMDA receptor antagonists, other therapeutics.

Alzheimer’s Disease Treatment Global Market Report 2021: COVID-19 Growth And Change To 2030 is one of a series of new reports from The Business Research Company that provides Alzheimer’s disease treatment market overview, forecast Alzheimer’s disease treatment market size and growth for the whole market, Alzheimer’s disease treatment market segments, and geographies, Alzheimer’s disease treatment market trends, Alzheimer’s disease treatment market drivers, restraints, leading competitors’ revenues, profiles, and market shares.

Request For A Sample Of The Global Alzheimer’s Disease Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3409&type=smp

Here Is A List Of Similar Reports By The Business Research Company:
Central Nervous System Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2020-30-covid-19-implications-and-growth

Anti-Parkinson Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report-2020-30-covid-19-growth-and-change

Neurodegenerative Disorder Therapeutics Global Market Report 2021: COVID-19 Growth And Change To 2030
https://www.thebusinessresearchcompany.com/report/neurodegenerative-disorder-therapeutics-market-global-report

Interventional Neurology Devices And Equipment Global Market Report 2021: COVID-19 Impact and Recovery to 2030
https://www.thebusinessresearchcompany.com/report/interventional-neurology-devices-and-equipment-global-market-report

Retirement Communities Market – By Type (Continuing Care Retirement Communities, Rest Homes, Assisted Living Facilities, Assisted Living Facilities With Nursing Care), By Region, Opportunities And Strategies – Global Forecast To 2023
https://www.thebusinessresearchcompany.com/report/retirement-communities-market

Interested to know more about The Business Research Company?
Read more about us at https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology. TBRC excels in company, market, and consumer research.

Call us now for personal assistance with your purchase:
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Oliver Guirdham
The Business Research Company
20 7193 0708
info@tbrc.info
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

The Sturge-Weber Foundation Announces the First National Million Miles for Sturge-Weber Syndrome Fundraising Campaign

Million Miles Campaign logo for the Sturge-Weber Foundation

The official logo for the 1st annual Million Miles for Sturge-Weber Syndrome Campaign

April 1st marks the opening of the First National Sturge-Weber Foundation (SWF) Million Miles for Sturge-Weber Syndrome (SWS) Fundraising Campaign.

HOUSTON, TEXAS, UNITED STATES, April 1, 2021 /EINPresswire.com/ — April 1st marks the opening of the First National Sturge-Weber Foundation (SWF) Million Miles for Sturge-Weber Syndrome (SWS) Fundraising Campaign. The event will take place virtually, across the United States from April 1st through June 30th in an effort to provide more public awareness of SWS as well as raise funding for patient/caregiver programs and critical research. Several corporations have joined SWF by sponsoring this event: UCB Pharmaceuticals, Qlaris Bio Ocular Therapeutics , Axiom Advisory Group, Coolibar and Washington Institute of Dermatologic Laser Surgery.

SWF collaborates with over 23 Clinical Care Network centers nationally (CCN), that provide expert treatment and research study on the various conditions associated with SWS. The CCNs are taking an active role in this campaign as “Team Leaders”, building teams of participants to run, walk, cycle or wheelchair miles to reach one million miles. All participants will try to achieve 100,000 steps within the 90 day period.

This fundraising campaign is open to anyone interested in getting outside to exercise and would like a great cause as incentive. To learn more or participate, individuals may visit the SWF website at https://sturge-weber.org/participate/. Participants may join an established team at one of the SWF CCNs or on their own. Centers that are participating are: Bascom Palmer Eye Institute; Boston Children’s Hospital; Cincinnati Children’s Hospital; Cook Children’s Medical Center; Dell Children’s Medical Center; The Ann and Robert H. Lurie Children’s Hospital; Mayo Clinic-Minnesota; Mayo Clinic-Arizona; Mayo Clinic-Florida; University of Michigan Mott Children’s Hospital; Nationwide Children’s Hospital; Nemours duPont Hospital for Children; NYU Langone Medical Center; Rady Children’s Hospital; Seattle Children’s Hospital; Texas Children’s Hospital; University of Illinois at Chicago Medical Center; University of North Carolina-Chappell Hill; University of California – San Francisco; University of Utah; Will’s Eye Institute/Jefferson Hospital and UC Davis Children’s Hospital, Sacramento.

The Texas Children’s Hospital CCN will hold a “Million Miles Kick-off” event along with the SWF home office in Houston, TX on Saturday, April 10, 2021. Time and location to be announced via social media and the SWF website (https://www.facebook.com/sturgeweberfoundation;
https://www.instagram.com/thesturgeweberfoundation/;
https://twitter.com/SturgeWeber; www.sturge-weber.org)

The Sturge-Weber Foundation is a registered 501(c)3 non-profit organization that exists to provide support for patients and families living with SWS, fund research and clinical trials, and host educational programs and conferences to inform the public, professionals and those diagnosed with the most current information. For additional information, visit www.sturge-weber.org.

Susan Finnell
The Sturge-Weber Foundation
+1 973-895-4445
sfinnell@sturge-weber.org
Visit us on social media:
Facebook
Twitter


Source: EIN Presswire

The 508 PV UV-visible-NIR Spectrophotometer for Your Microscope

Add spectroscopy to your microscope with the 508PV

Add spectroscopy to your microscope with the 508 PV from CRAIC Technologies

The 508 PV™ adds to your microscope to give you UV-visible-NIR absorbance, reflectance, fluorescence and polarization spectra and imaging.

SAN DIMAS, CA, UNITED STATES, April 1, 2021 /EINPresswire.com/ — CRAIC Technologies, the worlds leading innovator of UV-visible-NIR microspectroscopy solutions, is proud to introduce the 508 PV™ UV-visible-NIR spectrophotometer for your microscope. The 508 Perfect Vision™ is designed to be added to an open photoport of a microscope or probe station so that you can non-destructively analyze the spectra of many types of microscopic samples. Featuring CRAIC Technologies' cutting edge Lightblades™ spectrophotometers and proprietary optical interface technologies, the 508 PV™ can acquire spectra of microscopic sample areas by absorbance, reflectance, polarization, luminescence and fluorescence, in addition to high-resolution color images, when attached to properly configured microscopes. Applications are numerous and include characterization of new materials, measurement of surface plasmon resonance, graphene, vitrinite reflectance of coal and high resolution colorimetric and relative intensity mapping of flat panel displays. Thin film thickness of microscopic areas can also be measured using the 508 PV™. Combined with CRAIC Technologies Traceable Standards, which are specifically designed for use with microspectrophotometers and traceable to Standard Reference Materials from NIST, the 508 PV™ spectrophotometer is a cost effective micro-analysis tool for any laboratory or manufacturing facility.

“CRAIC Technologies has been an innovator in the field of UV-visible-NIR microanalysis since its founding. We have helped to advance the field of microscale analysis with innovative instrumentation, software, research and teaching. The 508 PV™ microscope spectrophotometer is the ideal tool for a laboratory or production line due the fact that it can add so many capabilities to a microscope or probe station. It can also be used to upgrade older microspectrophotometers with cutting edge detectors, electronics and software” states Dr. Paul Martin, President of CRAIC Technologies. “The 508 PV™ also features our proprietary Lightblades™ spectrophotometers and optical interface technology for improved performance and enhanced flexibility. With the addition of advanced spectroscopic, data analysis, film thickness and colorimetric software, this tool is perfect for any environment.”

The 508 PV™ spectrophotometer integrates CRAIC Technologies Lightblades™ spectrophotometer with a sophisticated optical interface hardware and powerful, easy-to-use Lambdafire™ software. Lightblades™ are spectrophotometers designed and built by CRAIC Technologies specifically for microscale analysis. This new level of sensitivity and stability give us a flexible instrument that is custom designed to add to a microscopes photoport and rapidly acquire high quality spectra from microscopic samples. Sophisticated software, high resolution imaging, permanently calibrated variable apertures and other innovations all yield a new level of sophistication for microanalysis. With high sensitivity, durable design, ease-of-use, imaging and spectroscopic techniques and the support of CRAIC Technologies, the 508 PV™ is more than just a scientific instrument…it is a great solution to your analytical challenges.

For more information on the 508 PV™ microscope spectrophotometer and the Perfect Vision for Science™, visit microspectra.com .

Paul Martin
CRAIC Technologies
+1 310-573-8180
paul.martin@microspectra.com
Visit us on social media:
Facebook
Twitter

Introducing the 508PV microscope spectrophotometer


Source: EIN Presswire

HealthViewX launches Digital Health Management, a Personalized Digital Care Ecosystem

HealthViewX Digital Health Management Platform

HealthViewX Digital Health Management Platform

HealthViewX announced the launch of its cutting-edge Digital Chronic and Post-Acute Care Management system, Digital Health Management [DHM].

PLANO, TX, UNITED STATES, April 1, 2021 /EINPresswire.com/ — HealthViewX, a leading global healthcare technology company, announced the launch of its cutting-edge Digital Chronic and Post-Acute Care Management system, Digital Health Management [DHM].

With this product, clinical providers are empowered to transform care delivery and significantly enhance patient engagement via a comprehensive, integrated digital health ecosystem. HealthViewX’s DHM combines technological innovation with transformational services to give patients the right care at the right time at the right location at the appropriate level.

HealthViewX is releasing smart, intuitive, and personalized 360 digital care ecosystems for over 70 plus disease conditions including
– Diabetes
– Hypertension
– Pain Management
– Weight Management
– Behavioral Health Management

"In a nutshell, we are attempting to add exponential value to value-based care. Studies across the globe find that patient outcome is largely driven by patient decisions outside the clinical care setting. Providers are however severely constrained in influencing these outcome decisions being made on a daily basis. Our custom DHM solution set allows a clinician to not only provide contextualized guidance, support, and interventions but also captures real-time patient-reported outcome and experience measures. Over time these data points serve as a compelling backdrop to help clinicians provide curated custom services to each and every patient”, said Subbiah Viswanathan, CEO and Co-Founder of HealthViewX.

Significance of a new-age Digital Health Management:
According to Forrester Consulting’s 2020 Healthcare Consumer Experience Study,
40% – Uptick in consumers who have switched provider because of a poor digital experience since 2019
52% – Have seen improvements as a result of more virtual care and better administrative experiences
68% – Want to customize their healthcare experience
65% – Leave a positive review if their provider offered a great digital experience

There is a global need for a cutting-edge digital Chronic and Post-Acute Care Management system and HealthViewX has built just that!

About HealthViewX: (A Payoda Technology, Inc. Company)
HealthViewX is an end-to-end care orchestration technology company that enables superior convenience and seamless integration of the clinical and service experience of patients, physicians, and provider entities by leveraging its proprietary software platform and comprehensive solution portfolio.

Its digital transformation moonshot is aimed at building a human-centric healthcare ecosystem to change the patient experience and enhance the provider-patient partnership. HealthViewX is a spin-off from parent company Payoda Technology, Inc., and is headquartered in the U.S., with offices in major cities across the world. For more information, visit www.healthviewx.com

Vignesh E
HealthViewX
+1 214-461-0242
email us here


Source: EIN Presswire

Media must help to facilitate evidence-informed policies on road safety

A new study by The George Institute has found that media in India does not follow WHO road safety reporting guidelines

Media is a critical gatekeeper, drives the narrative and influences policy response. We urge media to help facilitate evidence -informed policies for road safety.””

— Jagnoor Jagnoor

NEW DELHI, DELHI, INDIA, April 1, 2021 /EINPresswire.com/ — Road traffic collisions are a major contributor to injury-related deaths in India but advocacy and effective action to mitigate this has been limited. Media coverage of road traffic collisions may influence preventative action and influence the understanding, prioritisations and actions taken by both individuals and decision makers towards improving safety.

While the World Health Organisation (WHO) has detailed guidelines on reporting on road safety that provides journalists direction on covering road traffic collisions to influence evidence- based action, a new study by researchers from The George Institute for Global Health published in the BMJ Global Health today titled “Media coverage and framing of road safety in India” found that the most common media coverage was on single collisions which was not a WHO recommended story angle.

Researchers conducted an analysis of Indian media in English to assess whether coverage met the WHO’s Reporting on Road Safety guidelines for evidence- based reporting of road traffic collisions. A total of 458 English- language articles published online between March 2018 and February 2019 were assessed against the seven recommended story angles and seven recommended key elements in the WHO guidelines.

“The most common story angle was descriptions of single collisions, which was not a WHO- recommended story angle. These included limited key elements such as use of human story or linking to road safety risks or evidence- based solutions,” said Medhavi Gupta, Research assistant and PhD candidate, injury program, at the George Institute.

Targeted media coverage of system- level evidence- based solutions to road traffic collisions was also lacking. journalists were not incorporating important elements in their articles such as human stories and discussion of broader economic and health impacts and were not incorporating a range of stakeholder voices, she added.

However, some articles did follow the WHO recommended story angles with 22.1 per cent discussing specific road safety solutions and a further 6.3 per cent discussing vulnerable groups. Almost all articles avoided the use of technical language, but only 2 per cent explicitly stated that road traffic collisions were preventable. More than half identified at least one evidence- based solution. Very few articles discussed economic or health impacts of road traffic collisions.

“Indian media in English can improve reporting by focusing on human stories and documenting experiences of those injured in road traffic collisions. Coverage should also focus more on evidence- based solutions, emphasising the systems approach which encourages government action rather than changes to individual behaviour,” said Jagnoor Jagnoor, Head Injury Division at The George Institute.

“We recommend that media coverage of road traffic collisions in India and other contexts can be improved by putting greater focus on system- level evidence- based solutions, policies and discussing injuries in addition to deaths,” said Jagnoor, adding “ Policies are socially constructed phenomena. Media is a critical gatekeeper, drives the narrative and influences policy response. We urge media to help facilitate evidence -informed policies for road safety.”

KANNAN KRISHNASWAMY
GEORGE INSTITUTE FOR GLOBAL HEALTH
+91 99111 51783
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

IVI and Institut Pasteur Korea Sign MOU for Research and Development of Infectious Disease Therapeutics and Vaccines

GYEONGDO-DO AND SEOUL, REPUBLIC OF KOREA, April 1, 2021 /EINPresswire.com/ — The International Vaccine Institute (IVI) and the Institut Pasteur Korea (IPK) signed a memorandum of understanding (MOU) for mutual collaboration in the research and development of therapeutics and vaccines for infectious diseases.

The MOU signing ceremony, held at IVI headquarters on March 31, was attended by Dr. Youngmee Jee, CEO, and Dr. Spencer Shorte, CSO from IPK, as well as Dr. Jerome Kim, Director General, and Dr. Manki Song, Deputy Director General of Science from IVI.

Towards the shared goal of improving public health, the IPK and IVI will promote research collaboration and information exchange, holding joint workshops and seminars to connect biomedical scientists and infectious disease experts of the two organizations and their partners worldwide.

In particular, the collaboration combines IPK’s research and technology in infectious disease and IVI’s capabilities and know-how in developing and designing new vaccines and in supporting clinical trials to accelerate new therapeutics and vaccine development. IPK and IVI have common fields of research interest in COVID-19, MERS, Dengue, TB, etc.

IPK stands at the forefront of developing preventive and therapeutic strategies by employing state-of-the-art screening platforms that enable researchers to study and analyze the physiological and chemical phenomena in cells, such as infection, and identify potent candidates. Especially, IPK will apply its research on viral immune responses and immunopathology to facilitate vaccine research, such as understanding the in-vivo immune response to viruses and identifying novel immune-regulatory molecules using the screening platform.

“The IPK and IVI will together create synergy utilizing each other’s research capabilities and global network,” IPK CEO Dr. Youngmee Jee said. “Through the collaboration with IVI, which is internationally renowned for expertise and capabilities in the field of vaccine development for infectious diseases, IPK will make an opportunity for expanding the core R&D expertise in infectious diseases, and further strive in contributing to public health and responding to global threats.” Dr. Jee served as a member of the Board of Trustees of IVI from 2016 to 2019.

IVI, hosted by the Republic of Korea, is the world’s only international organization devoted exclusively to discovery, development and delivery of vaccines against infectious diseases. IVI is developing vaccines for the world’s neglected and emerging diseases including COVID-19 through public-private partnerships with companies and organizations in Korea and globally.

“IVI is privileged to partner with IPK, the international institute established by the scientific cooperation between Korea and France and a member of the Institut Pasteur International Network, in our concerted efforts to find vaccine and therapeutics solutions to global health threats,” said IVI Director General Dr. Jerome Kim. “This partnership may open a new horizon for vaccine discovery and development by integrating IVI’s proven track records in vaccine discovery and development with IPK’s advanced screening platform, coupled with the extensive global partnership networks of the two organizations.”

###

About IVI

The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). IVI has 36 signatory countries and the World Health Organization on its treaty, including Korea, Sweden, India, and Finland as state funders. Our mandate is to make vaccines available and accessible for the world’s most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance.

About IPK

Institut Pasteur Korea (IPK) is a non-profit infectious disease-focused research institute established in 2004 as a part of the scientific cooperation between the Rep. of Korea and France. To address unmet global health issues, such as COVID-19, hepatitis, tuberculosis, antibiotic resistance, and cancer, IPK utilizes its core research capabilities, including in-house developed cell-based screening platforms, to understand disease mechanisms and accelerate the development of new treatments. As a member of the Institut Pasteur International Network (IPIN), constituting 32 member institutes in 25 countries across the five continents, IPK plays a key role in driving early drug discovery within the network. By providing fundamental technologies to bridge Korean and international bio-pharma science and promote multi-disciplinary projects globally, IPK stands at the forefront of drug discovery research that contributes to Korea’s scientific, intellectual, and technical resources and global infectious disease preparedness and response.

Aerie Em
International Vaccine Institute
aerie.em@ivi.int
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire